Analyzing...
Loading company...
Aster DM Healthcare Ltd. engages in the provision of healthcare solutions. The company is headquartered in Dubai, Karnataka and currently employs 30,330 full-time employees. The company went IPO on 2018-02-26. The Company’s segments include Hospitals, Clinics and Retail Pharmacies. The Hospitals segment comprises of hospitals and in-house pharmacies at the hospitals. The Clinics segment comprises of clinics and in-house pharmacies at the clinics. The Retail Pharmacies segment comprises standalone retail pharmacies and optical outlets. The firm also comprises healthcare consultancy services. Its geographical segments consist of gulf corporation council (GCC) States, including United Arab Emirates, Qatar, Oman, Kingdom of Saudi Arabia, Jordan, Kuwait, Bahrain, India and Rest of the world. The firm's healthcare services are offered under Aster, Medcare and Access brands. The firm operates over five medical centers, approximately six pharmacies, one full-fledged diagnostic center and a multispecialty Aster Hospital.
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹4,643 Cr service revenue.
Employee costs at 18.3% of revenue — primary cost driver.
“Plus the synergy element that we have guided that, you know, we expect 10 to 15% of EBITDA coming in form of synergies over the next two to three years.”
“mature units, which is approximately 60% of our revenue, delivered a 12.”
“revenue increased 19% year on year to 619 crores, highlighting the sustained strength of the core hospitals and the ability to grow on a elevated base established earlier in the year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 8.5%▼ | 9.0% |
| ROCE | 10.2%▼ | 10.4% |
| Net Margin | 8.1%▼ | 8.5% |
| EBITDA Margin | 20.8%▲ | 20.6% |
| Debt To Equity | 0.15x▼ | 0.16x |
| Rev Growth 3yr | -26.5%▼ | 14.4% |
| EPS Growth 3yr | -4.2%▼ | 9.9% |
| Employee Cost Ratio | 18.30x | - |
Historical valuation data not available.
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4,643 Cr +12.2% | ₹4,138 Cr +11.9% | ₹3,699 Cr -69.0% | ₹11,933 Cr +16.4% | ₹10,253 Cr +19.1% | ₹8,608 Cr -1.5% | ₹8,739 Cr +9.7% | ₹7,963 Cr |
| Other Income | ₹126 Cr -15.3% | ₹148 Cr +496.5% | ₹25 Cr -68.2% | ₹78 Cr +54.5% | ₹51 Cr +1.4% | ₹50 Cr +32.0% | ₹38 Cr +9.4% | ₹35 Cr |
| Total Income | ₹4,769 Cr +11.2% | ₹4,287 Cr +15.1% | ₹3,724 Cr -69.0% | ₹12,011 Cr +16.6% | ₹10,304 Cr +19.0% | ₹8,658 Cr -1.3% | ₹8,776 Cr +9.7% | ₹7,997 Cr |
| COGS | ₹1,049 Cr +11.8% | ₹938 Cr +2.5% | ₹916 Cr -74.1% | ₹3,532 Cr +22.1% | ₹2,892 Cr +13.5% | ₹2,549 Cr -3.3% | ₹2,635 Cr +8.9% | ₹2,420 Cr |
| ₹4,129 Cr +10.2% | ₹3,747 Cr +8.6% | ₹3,451 Cr -69.9% | ₹11,477 Cr +18.7% | ₹9,668 Cr +14.3% | ₹8,457 Cr +0.4% | ₹8,427 Cr +11.1% | ₹7,585 Cr | |
| Profit Before Tax | ₹607 Cr +23.8% | ₹490 Cr +79.8% | ₹273 Cr -49.0% | ₹534 Cr -16.1% | ₹636 Cr +215.7% | ₹202 Cr -39.0% | ₹330 Cr -19.6% | ₹411 Cr |
| Exceptional Items | (₹33 Cr) +34.8% | (₹50 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹20 Cr) | (₹2 Cr) |
| ₹143 Cr +6.1% | ₹134 Cr +137.8% | ₹57 Cr -5.2% | ₹60 Cr +66.5% | ₹36 Cr +31.5% | ₹27 Cr +77.0% | ₹15 Cr -64.2% | ₹43 Cr | |
| Net Profit | ₹427 Cr -92.1% | ₹5,408 Cr | ₹212 Cr -55.5% | ₹475 Cr -20.9% | ₹601 Cr +238.0% | ₹178 Cr -43.5% | ₹315 Cr -14.3% | ₹367 Cr |
| Profit (Owners) | ₹388 Cr -92.8% | ₹5,378 Cr | ₹129 Cr -69.6% | ₹425 Cr -19.2% | ₹526 Cr +256.0% | ₹148 Cr -46.6% | ₹277 Cr -17.0% | ₹333 Cr |
| Minority Interest | ₹39 Cr +29.6% | ₹30 Cr -63.5% | ₹82 Cr +62.7% | ₹51 Cr -32.6% | ₹75 Cr +149.5% | ₹30 Cr -20.9% | ₹38 Cr +11.3% | ₹34 Cr |
| Other Comprehensive Income | ₹0.36 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹46 Cr -76.7% | ₹199 Cr +112.9% | ₹93 Cr ↑ Recovery | (₹50 Cr) ↓ Decline | ₹145 Cr +131.7% | ₹62 Cr |
| EPS | ₹7.49 | ₹107.66 | ₹2.59 | ₹8.51 | ₹10.53 | ₹2.96 | ₹5.54 | ₹6.59 |
| Diluted Shares | ₹52 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹51 Cr |
| Profit Or Loss Of Associates | (₹37 Cr) -95.7% | (₹19 Cr) -66.8% | (₹11 Cr) ↓ Decline | ₹1 Cr +125.9% | ₹0.54 Cr -84.7% | ₹4 Cr ↑ Recovery | (₹0.19 Cr) +24.0% | (₹0.25 Cr) |
| Profit Loss From Discontinued Operations After Tax | ₹0.00 Cr -100.0% | ₹5,071 Cr | ₹7 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
Aster DM Quality Care Limited has informed the Exchange about schedule of Analyst/Investors call for quarter ended 30 June 2026
Aster DM Quality Care Limited has informed the Exchange about Credit Rating
ASTERDM: Members of the Exchange are hereby informed that the name of Aster DM Healthcare Limited will be changed to Aster DM Quality Care Limited w.e.f. July 28, 2026.
Aster DM Healthcare Limited has informed the Exchange about allotment of equity shares to the shareholders of transferor Company (QCIL) pursuant to the scheme of Amalgamation
Aster DM Healthcare Limited has informed the Exchange about Credit Rating- Revision
Aster DM Healthcare Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for quarter ended 30 June 2026
BCP Asia II Topco IV Pte ltd has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided ...
Aster DM Healthcare Limited has informed the Exchange about acquisition of Optionally Convertible Redeemable Preference Shares in an Associate Company
Aster DM Healthcare Limited has informed the Exchange about Acquisition
Aster DM Healthcare Limited has informed the Exchange about Investor Presentation
Aster DM Healthcare Limited has informed the Exchange about Schedule of meet
Dr. Mandayapurath Azad Moopen has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ...
Dr. Mandayapurath Azad Moopen has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ...
Aster DM Healthcare Limited has informed the Exchange about Transcript
Aster DM Healthcare Limited has informed the Exchange about Copy of Newspaper Publication regarding audited financial results of the Company for the quarter and year ended March 31, 2026.